Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992598 | 0.93 | CES2 (0.44) | CES2LTA4HMEN1FAAHMAPK1 | |
| SCHEMBL18751717 | 0.90 | CES2 (0.48) | CES2LTA4HTSHRMEN1FAAH | |
| SCHEMBL9973392 | 0.90 | CES2 (0.48) | CES2LTA4HTSHRMEN1FAAH | |
| SCHEMBL9973396 | 0.90 | CES2 (0.48) | CES2LTA4HTSHRMEN1FAAH | |
| SCHEMBL9973391 | 0.90 | CES2 (0.48) | CES2LTA4HTSHRMEN1FAAH | |
| SCHEMBL11918238 | 0.89 | ALDH1A1 (0.45) | CES2LTA4HLMNA | |
| SCHEMBL10299251 | 0.89 | SLC22A6 (0.58) | SLC22A6TSHRMEN1KMT2ALMNA | |
| SCHEMBL22644547 | 0.87 | LTA4H (0.32) | CES2LTA4HMEN1FAAHMAPK1 | |
| SCHEMBL620412 | 0.86 | CA1 (0.36) | — | |
| SCHEMBL2532884 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-11-23 | — | — | US | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-09-28 | — | — | US | disclosed |
| US-20230287204-A1 | OXIDIZED POLYISOBUTENE COMPOUNDS AND METHODS OF MAKING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-09-14 | — | — | US | disclosed |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | SUTRO BIOPHARMA, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012046062-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | SHIRE, LLC (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | SHIRE LLC (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20100113367-A1 | PEPTIDE-CYTOTOXIC CONJUGATES | IPSEN PHARMA S.A.S. (FR) | 2010-05-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20070093645-A1 | Peptide vectors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7169814-B2 | Guanidinium transport reagents and conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357767-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | SNRPE, DDX21, DCLRE1B | CES2 4431/4885LTA4H 4640/4885SLC22A6 1638/4885 |
| US-20230374513-A1 | NOVEL COMPOUND AND APPLICATION THEREOF | GALNT6, GALNT3, GALNT14 | CES2 3121/4885LTA4H 3846/4885SLC22A6 682/4885 |
| US-20100113367-A1 | PEPTIDE-CYTOTOXIC CONJUGATES | TP53, VIP, MCL1 | CES2 3596/4885LTA4H 3014/4885SLC22A6 1428/4885 |
| US-20110098278-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | CES2 1531/4885LTA4H 1400/4885SLC22A6 1199/4885 |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CES2 4871/4885LTA4H 4242/4885SLC22A6 2696/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | CES2 448/4885LTA4H 1003/4885SLC22A6 1166/4885 |
| US-11744876-B2 | Immunomodulator antibody drug conjugates and uses thereof | FCGR1A, FCGR2A, FCGRT | CES2 3619/4885LTA4H 592/4885SLC22A6 3423/4885 |
| US-20230301988-A1 | INHIBITORS OF SARS COV-2 INFECTION AND USES THEREOF | CTSV, ACE2, CTSL | CES2 294/4885LTA4H 609/4885SLC22A6 1993/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | CES2 4371/4885LTA4H 4139/4885SLC22A6 2822/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CES2 1630/4885LTA4H 3944/4885SLC22A6 3633/4885 |
| US-20120184532-A1 | GALANTAMINE AMINO ACID AND PEPTIDE PRODRUGS AND USES THEREOF | PEPD, VIP, GALR1 | CES2 1531/4885LTA4H 1400/4885SLC22A6 1199/4885 |
| US-20070093645-A1 | Peptide vectors | TP53, VIP, XIAP | CES2 4231/4885LTA4H 3720/4885SLC22A6 1453/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | CES2 3035/4885LTA4H 3856/4885SLC22A6 672/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CES2 941/4885LTA4H 2929/4885SLC22A6 322/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | CES2 941/4885LTA4H 2929/4885SLC22A6 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.